This is the authors' abstract. We don't add key points for this paper.
Agonists at the α 2 adrenergic receptor produce sedation, increase focus, provide analgesia, and induce centrally mediated hypotension and bradycardia, yet neither their dynamic interactions with adrenergic receptors nor their modulation of neuronal circuit activity is completely understood. Photoaffinity ligands of α 2 adrenergic agonists have the potential both to capture discrete moments of ligand–receptor interactions and to prolong naturalistic drug effects in discrete regions of tissue in vivo. We present here the synthesis and characterization of a novel α 2 adrenergic agonist photolabel based on the imidazole medetomidine called azi-medetomidine . Azi-medetomidine shares protein association characteristics with its parent compound in experimental model systems and by molecular dynamics simulation of interactions with the α 2A adrenergic receptor. Azi-medetomidine acts as an agonist at α 2A adrenergic receptors, and produces hypnosis in Xenopus laevis tadpoles. Azi-medetomidine competes with the α 2 agonist clonidine at α 2A adrenergic receptors, which is potentiated by photolabeling, and azi-medetomidine labels moieties on the α 2A adrenergic receptor as determined by mass spectrometry in a manner consistent with a simulated model. This novel α 2 adrenergic agonist photolabel can serve as a powerful tool for in vitro and in vivo investigations of adrenergic signaling.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
McKinstry-Wu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: